Ken Griffin Capricor Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Capricor Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 36,700 shares of CAPR stock, worth $620,597. This represents 0.0% of its overall portfolio holdings.

Number of Shares

36,700

Previous 22,900 60.26%

Holding current value

$620,597

Previous $155,000 12.9%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$4.63 - $7.09 $167,193 - $256,026	36,111 Added 117.23%	66,914 $319,000
Q1 2024 May 15, 2024	BUY	$3.61 - $6.88 $111,198 - $211,924	30,803 New	30,803 $209,000
Q3 2023 Nov 14, 2023	SELL	$3.42 - $7.85 $84,771 - $194,577	-24,787 Reduced 54.3%	20,861 $71,000
Q2 2023 Aug 14, 2023	BUY	$3.76 - $5.05 $115,326 - $154,893	30,672 Added 204.81%	45,648 $218,000
Q1 2023 May 15, 2023	SELL	$3.78 - $5.03 $46,626 - $62,045	-12,335 Reduced 45.16%	14,976 $63,000
Q4 2022 Feb 14, 2023	SELL	$3.36 - $6.55 $29,994 - $58,471	-8,927 Reduced 24.63%	27,311 $105,000
Q3 2022 Nov 14, 2022	SELL	$3.61 - $6.08 $38,316 - $64,533	-10,614 Reduced 22.65%	36,238 $217,000
Q2 2022 Aug 15, 2022	SELL	$2.89 - $4.51 $33,971 - $53,015	-11,755 Reduced 20.06%	46,852 $163,000
Q1 2022 May 16, 2022	SELL	$2.83 - $5.68 $60,083 - $120,592	-21,231 Reduced 26.59%	58,607 $201,000
Q4 2021 Feb 14, 2022	SELL	$2.89 - $4.16 $91,647 - $131,921	-31,712 Reduced 28.43%	79,838 $233,000
Q3 2021 Nov 15, 2021	BUY	$3.8 - $5.23 $159,185 - $219,089	41,891 Added 60.14%	111,550 $448,000
Q2 2021 Aug 16, 2021	BUY	$3.16 - $5.72 $73,820 - $133,624	23,361 Added 50.46%	69,659 $357,000
Q1 2021 May 17, 2021	BUY	$3.63 - $7.93 $34,829 - $76,088	9,595 Added 26.14%	46,298 $217,000
Q4 2020 Feb 16, 2021	BUY	$3.43 - $5.23 $4,308 - $6,568	1,256 Added 3.54%	36,703 $126,000
Q3 2020 Nov 16, 2020	BUY	$4.08 - $9.81 $20,783 - $49,972	5,094 Added 16.78%	35,447 $186,000
Q2 2020 Aug 14, 2020	BUY	$1.0 - $8.5 $6,474 - $55,029	6,474 Added 27.11%	30,353 $140,000
Q1 2020 May 15, 2020	BUY	$0.94 - $2.02 $11,730 - $25,207	12,479 Added 109.46%	23,879 $28,000
Q4 2019 Feb 14, 2020	BUY	$1.04 - $3.55 $11,856 - $40,470	11,400 New	11,400 $15,000

Others Institutions Holding CAPR

# of Institutions

Shares Held

6.6M

Call Options Held

260K

Put Options Held

576K

View Full List

About CAPRICOR THERAPEUTICS, INC.

Ticker CAPR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,346,200
Market Cap $412M
Description
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...

More about CAPR

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account